TY - JOUR AU - Ferlay, J. AU - Steliarova-Foucher, E. AU - Lortet-Tieulent, J. AU - Rosso, S. AU - Coebergh, J. W. AU - Comber, H. AU - Forman, D. AU - Bray, F. PY - 2013 DA - 2013// TI - Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.027 DO - 10.1016/j.ejca.2012.12.027 ID - Ferlay2013 ER - TY - STD TI - Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovic Z, et al. Seer cancer statistics review, 1975-2013. National Cancer Institute. 2015; ID - ref2 ER - TY - JOUR AU - Guinney, J. AU - Dienstmann, R. AU - Wang, X. AU - de Reynies, A. AU - Schlicker, A. AU - Soneson, C. AU - Marisa, L. AU - Roepman, P. AU - Nyamundanda, G. AU - Angelino, P. PY - 2015 DA - 2015// TI - The consensus molecular subtypes of colorectal cancer JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3967 DO - 10.1038/nm.3967 ID - Guinney2015 ER - TY - JOUR AU - Missiaglia, E. AU - Jacobs, B. AU - D'Ario, G. AU - Di Narzo, A. F. AU - Soneson, C. AU - Budinska, E. AU - Popovici, V. AU - Vecchione, L. AU - Gerster, S. AU - Yan, P. PY - 2014 DA - 2014// TI - Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features JO - Annals of oncology : official journal of the European Society for Medical Oncology VL - 25 UR - https://doi.org/10.1093/annonc/mdu275 DO - 10.1093/annonc/mdu275 ID - Missiaglia2014 ER - TY - JOUR AU - Yamauchi, M. AU - Lochhead, P. AU - Morikawa, T. AU - Huttenhower, C. AU - Chan, A. T. AU - Giovannucci, E. AU - Fuchs, C. AU - Ogino, S. PY - 2012 DA - 2012// TI - Colorectal cancer: a tale of two sides or a continuum? JO - Gut VL - 61 UR - https://doi.org/10.1136/gutjnl-2012-302014 DO - 10.1136/gutjnl-2012-302014 ID - Yamauchi2012 ER - TY - JOUR AU - Lee, G. H. AU - Malietzis, G. AU - Askari, A. AU - Bernardo, D. AU - Al-Hassi, H. O. AU - Clark, S. K. PY - 2015 DA - 2015// TI - Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review JO - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology VL - 41 UR - https://doi.org/10.1016/j.ejso.2014.11.001 DO - 10.1016/j.ejso.2014.11.001 ID - Lee2015 ER - TY - JOUR AU - Dejea, C. M. AU - Wick, E. C. AU - Hechenbleikner, E. M. AU - White, J. R. AU - Mark Welch, J. L. AU - Rossetti, B. J. AU - Peterson, S. N. AU - Snesrud, E. C. AU - Borisy, G. G. AU - Lazarev, M. PY - 2014 DA - 2014// TI - Microbiota organization is a distinct feature of proximal colorectal cancers JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1406199111 DO - 10.1073/pnas.1406199111 ID - Dejea2014 ER - TY - STD TI - Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA oncology. 2016; ID - ref8 ER - TY - STD TI - Venook A, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, Shaw J, Atikins J, Horvath LE, Polite B et al: Impact of primary tumor location on overall survival and progression free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34; suppl 4S: abstr 493 2016. ID - ref9 ER - TY - JOUR AU - Holch, J. W. AU - Ricard, I. AU - Stintzing, S. AU - Modest, D. P. AU - Heinemann, V. PY - 2016 DA - 2016// TI - The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials JO - Eur J Cancer VL - 70 UR - https://doi.org/10.1016/j.ejca.2016.10.007 DO - 10.1016/j.ejca.2016.10.007 ID - Holch2016 ER - TY - JOUR AU - Barault, L. AU - Veyrie, N. AU - Jooste, V. AU - Lecorre, D. AU - Chapusot, C. AU - Ferraz, J. M. AU - Lievre, A. AU - Cortet, M. AU - Bouvier, A. M. AU - Rat, P. PY - 2008 DA - 2008// TI - Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers JO - Int J Cancer VL - 122 UR - https://doi.org/10.1002/ijc.23388 DO - 10.1002/ijc.23388 ID - Barault2008 ER - TY - STD TI - Lenz H-J, Ou F-S, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 2017;35(15_suppl):3511–1. ID - ref12 ER - TY - STD TI - Boeckx N, Toler A, Op de Beeck K, Kafatos G, Deschoolmeester V, Rolfo C, Lowe K, Van Camp G, Demonty G, Peeters M: Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC. Ann Oncol (2016) 27 (suppl 6): doi: 10.1093/annonc/mdw36337. UR - https://doi.org/10.1093/annonc/mdw36337 ID - ref13 ER - TY - JOUR AU - Lleonart, M. E. AU - Garcia-Foncillas, J. AU - Sanchez-Prieto, R. AU - Martin, P. AU - Moreno, A. AU - Salas, C. AU - Ramon y Cajal, S. PY - 1998 DA - 1998// TI - Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: different clinical and molecular implications JO - Cancer VL - 83 UR - https://doi.org/3.0.CO;2-R DO - 3.0.CO;2-R ID - Lleonart1998 ER - TY - JOUR AU - Ince, W. L. AU - Jubb, A. M. AU - Holden, S. N. AU - Holmgren, E. B. AU - Tobin, P. AU - Sridhar, M. AU - Hurwitz, H. I. AU - Kabbinavar, F. AU - Novotny, W. F. AU - Hillan, K. J. PY - 2005 DA - 2005// TI - Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab JO - J Natl Cancer Inst VL - 97 UR - https://doi.org/10.1093/jnci/dji174 DO - 10.1093/jnci/dji174 ID - Ince2005 ER - TY - JOUR AU - Oden-Gangloff, A. AU - Di Fiore, F. AU - Bibeau, F. AU - Lamy, A. AU - Bougeard, G. AU - Charbonnier, F. AU - Blanchard, F. AU - Tougeron, D. AU - Ychou, M. AU - Boissiere, F. PY - 2009 DA - 2009// TI - TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy JO - Br J Cancer VL - 100 UR - https://doi.org/10.1038/sj.bjc.6605008 DO - 10.1038/sj.bjc.6605008 ID - Oden-Gangloff2009 ER - TY - STD TI - Di Fiore F, Lamy A, Blanchard F, Oden-Gangloff A, Sesboüé R, Sabourin JC, Frebourg T, Michel P, Laurent-Puig P: TP53 mutations in irinotecan-refractory KRAS wt-BRAF wt metastatic colorectal cancer patients treated with cetuximab-based chemotherapy. J Clin Oncol 29: 2011 (suppl 4; abstr 426). ID - ref17 ER - TY - JOUR AU - Di Bartolomeo, M. AU - Pietrantonio, F. AU - Perrone, F. AU - Dotti, K. F. AU - Lampis, A. AU - Bertan, C. AU - Beretta, E. AU - Rimassa, L. AU - Carbone, C. AU - Biondani, P. PY - 2014 DA - 2014// TI - Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT JO - Target Oncol VL - 9 UR - https://doi.org/10.1007/s11523-013-0283-8 DO - 10.1007/s11523-013-0283-8 ID - Di Bartolomeo2014 ER - TY - JOUR AU - Ciardiello, F. AU - Normanno, N. AU - Maiello, E. AU - Martinelli, E. AU - Troiani, T. AU - Pisconti, S. AU - Giuliani, F. AU - Barone, C. AU - Carteni, G. AU - Rachiglio, A. M. PY - 2014 DA - 2014// TI - Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial JO - Annals of oncology: official journal of the European Society for Med Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu230 DO - 10.1093/annonc/mdu230 ID - Ciardiello2014 ER - TY - STD TI - Khan SA, Zeng Z, Shia J, Paty PB: EGFR gene amplification and KRAS mutation predict response to combination targeted therapy in metastatic colorectal cancer. Pathology oncology research: POR 2016. ID - ref20 ER - TY - STD TI - Kasper S, Meiler J, Knipp H, Höhler T, Reimer P, Steinmetz HT, Berger W, Linden G, Ting S, Markus P et al: Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer. Annals of Oncology (2016) 27 (6): 149–206 101093/annonc/mdw370. ID - ref21 ER - TY - JOUR AU - Hsu, H. C. AU - Thiam, T. K. AU - YJ, L. AU - Yeh, C. Y. AU - Tsai, W. S. AU - You, J. F. AU - Hung, H. Y. AU - Tsai, C. N. AU - Hsu, A. AU - Chen, H. C. PY - 2016 DA - 2016// TI - Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.8076 DO - 10.18632/oncotarget.8076 ID - Hsu2016 ER - TY - STD TI - Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst. 2014;106(7) ID - ref23 ER - TY - STD TI - Folprecht G, Beer P, Salazar R, Roth A, Aust D, Salgado R, Laurent-Puig P, Tabernero J, Arnold D, Stein A et al: Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor. Annals of Oncology (2016) 27 (6): 149–206 doi: 10.1093/annonc/mdw370. UR - https://doi.org/10.1093/annonc/mdw370 ID - ref24 ER - TY - JOUR AU - Huang, S. AU - Benavente, S. AU - Armstrong, E. A. AU - Li, C. AU - Wheeler, D. L. AU - Harari, P. M. PY - 2011 DA - 2011// TI - p53 modulates acquired resistance to EGFR inhibitors and radiation JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-0128 DO - 10.1158/0008-5472.CAN-11-0128 ID - Huang2011 ER - TY - JOUR AU - Huether, A. AU - Hopfner, M. AU - Baradari, V. AU - Schuppan, D. AU - Scherubl, H. PY - 2005 DA - 2005// TI - EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer JO - Biochem Pharmacol VL - 70 UR - https://doi.org/10.1016/j.bcp.2005.09.007 DO - 10.1016/j.bcp.2005.09.007 ID - Huether2005 ER -